Survival Prediction and Frailty Evaluation for Patients with Metastatic Tumors

<p>Featuring: Joseph H Schwab, MD; Dan M Sciubba, MD; Ilya Laufer, MD</p> <p><br></p> <p>Disclosures:</p> <p>Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).&nbsp;</p> <p>Sciubba, Dan: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C). &nbsp;</p> <p>Laufer, Ilya : Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), SpineWave (B).&nbsp;</p> <p><br></p> <p>Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+</p>